skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Specific Issues in Antiretroviral Therapy for HIV-Infected Adolescents

(Last updated: February 12, 2014; last reviewed: February 12, 2014)

Panel Recommendations

Panel's Recommendations

  • Combination antiretroviral therapy (cART) regimens must be individually tailored to the adolescent (AIII).
  • Appropriate dosing of cART for adolescents may be complex, not always predictable, and dependent upon multiple factors, including body mass and composition and pubertal development (AII).
  • Effective and appropriate methods should be selected to reduce the likelihood of unintended pregnancy and to prevent secondary transmission of HIV to sexual partners (AI).
  • Providers should be aware of potential interactions between cART and hormonal contraceptives, which could lower contraceptive efficacy (AII*).
  • Alternative regimens that do not include efavirenz should be strongly considered in adolescent females who are trying to conceive or who are not using effective and consistent contraception because of the potential for teratogenicity with first-trimester efavirenz exposure, assuming these alternative regimens do not compromise the woman’s health (BIII). Adolescent females who require treatment with efavirenz should undergo pregnancy testing before initiation of treatment and receive counseling about potential fetal risk and desirability of avoiding pregnancy while receiving efavirenz-containing regimens (AIII).
  • Pediatric and adolescent care providers should prepare adolescents for the transition into adult care settings (AIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials in children with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = expert opinion
Studies that include children or children and adolescents but not studies limited to postpubertal adolescents



An increasing number of HIV-infected children who acquired HIV infection through perinatal transmission are now surviving into adolescence. They generally have had a long clinical course and extensive combination antiretroviral therapy (cART) history.1 Adolescents with non-perinatally acquired HIV infection generally follow a clinical course similar to that in adults. Because non-perinatally infected adolescents may be at the initial stages of their HIV disease, they may be potential candidates for early intervention and treatment.2

Dosing of Antiretroviral Therapy for HIV-Infected Adolescents 

Puberty is a time of somatic growth and sexual maturation, with females developing more body fat and males more muscle mass. These physiologic changes may affect drug pharmacokinetics (PK), which is especially important for drugs with a narrow therapeutic index that are used in combination with protein-bound medicines or hepatic enzyme inducers or inhibitors.

In addition, many antiretroviral (ARV) drugs (e.g., abacavir, emtricitabine, lamivudine, tenofovir, and some protease inhibitors [PIs]) are administered to children at higher weight- or surface area-based doses than would be predicted by direct extrapolation of adult doses. This is based upon reported PK data indicating more rapid drug clearance in children. With unboosted PI usage, continued use of these pediatric weight- or surface-area-based doses as a child grows during adolescence can result in medication doses that are higher than the usual adult doses. Data suggesting optimal doses for every ARV drug in adolescents are not available. Appendix A: Pediatric Antiretroviral Drug Information includes a discussion of data relevant to adolescents for individual drugs and notes the age listed on the drug label for adult dosing, when available. 

Adolescent Contraception, Pregnancy, and Antiretroviral Therapy 

HIV-infected adolescents may be sexually active. Reproductive plans including preconception care, contraception methods, and safer sex techniques for prevention of secondary HIV transmission should be discussed regularly (see U.S. Medical Eligibility Criteria for Contraceptive Use).4 For additional information please the Perinatal GuidelinesReproductive Options for HIV-Concordant and Serodiscordant Couples .5

The possibility of an unplanned pregnancy should also be considered when selecting a cART regimen for an adolescent female. The most vulnerable period in fetal organogenesis is the first trimester, often before pregnancy is recognized. Concerns about specific ARV drugs and birth defects should be promptly addressed to preclude misinterpretation or lack of adherence by adolescents with unexpressed plans for pregnancy.6 For additional information please see the Perinatal Guidelines.5 Alternative regimens that do not include efavirenz should be strongly considered in adolescent females who are trying to conceive or who are not using effective and consistent contraception because of the potential for teratogenicity with first-trimester efavirenz exposure, assuming these alternative regimens are acceptable to the provider and will not compromise the woman’s health.

Contraceptive-Antiretroviral Drug Interactions 

Several PI and non-nucleoside reverse transcriptase inhibitor drugs alter metabolism of oral contraceptives, resulting in possible decreases in ethinyl estradiol or increases in estradiol or norethindrone levels (see the Adult and Adolescent Antiretroviral Guidelines) ( These changes may decrease the effectiveness of the oral contraceptives or potentially increase the risk of estrogen- or progestin-related adverse effects. Some newer agents, such as integrase inhibitors (specifically raltegravir), appear to have no interaction with estrogen-based contraceptives.10 Providers should be aware of these drug interactions and consider alternative or additional contraceptive methods for patients receiving cART. 

Whether interactions with cART would compromise the contraceptive effectiveness of progestogen-only injectable contraceptives (such as depot medroxyprogesterone acetate [DMPA]) is unknown because these methods produce higher blood hormone levels than other progestogen-only oral contraceptives and combined oral contraceptives. In one study, the efficacy of DMPA was not altered in women receiving concomitant nelfinavir-, efavirenz-, or nevirapine-based treatment, with no evidence of ovulation during concomitant administration for 3 months, no additional adverse effects, and no clinically significant changes in ARV drug levels.11,12 At this time, concerns about loss of bone mineral density (BMD) with long-term use of DMPA with or without cART (specifically tenofovir)13 should not preclude use of DMPA as an effective contraceptive, unless there is clinical evidence of bone fragility. However, more active monitoring of BMD in young women on DMPA may need to be considered.13 Minimal information exists about drug interactions with use of newer hormonal contraceptive methods (e.g., the patch and vaginal ring).14 Women with HIV can use all available contraceptive methods, including intrauterine devices (IUD).4 Adolescents who want to become pregnant should be referred for preconception counseling and care, including discussion of special considerations with cART use during pregnancy (see the Perinatal Guidelines).5

HIV-Infected Pregnant Adolescents and Outcomes 

Pregnancy should not preclude the use of optimal therapeutic regimens. However, because of considerations related to prevention of perinatal transmission and maternal and fetal safety, timing of initiation of treatment and selection of regimens may be different for pregnant women than for nonpregnant females. Details regarding choice of cART regimen in pregnant HIV-infected women, including adolescents, are provided in the Perinatal Guidelines.5 Although information is limited about the pregnancies of adolescents who were HIV-infected perinatally, perinatal HIV transmission outcomes in this population appear similar to those in adult cohorts;15-18 however, there may be differences in pregnancy-related morbidities. Kenny et al19 reported pregnancy outcomes from the United Kingdom and Ireland in a group of 30 adolescents who were perinatally HIV-infected or who acquired HIV infection at a young age. Few of these pregnancies were planned and in many cases, the partner was unaware of the mother’s HIV status. Rates of elective termination, miscarriage, and prematurity were high. The rate of prematurity was twice that in the general adolescent population of Europe. Many of the women had an AIDS diagnosis before pregnancy, but only one infant was HIV-infected. Although the rate of perinatal transmission is reassuring, this study highlights some of the major challenges in caring for pregnant, perinatally HIV-infected youth.

Comparisons of pregnancy incidence and outcomes between perinatally infected and non-perinatally infected youth are few and may offer special insight into the effects of prolonged HIV infection on pregnancy-related sequelae. Agwu et al20 retrospectively evaluated pregnancies at four clinics. Non-perinatally infected youth were more likely to have one or more pregnancies despite similar age at first pregnancy between groups. They also appeared to have more premature births and spontaneous abortions, but that is tempered by the fact that the perinatally infected youth were more likely to have an elective termination. The perinatal transmission rate for the entire cohort was 1.5%. Similar results were found in several other studies.21,22 However, in a single-center review of perinatal versus non-perinatal birth outcomes, infants born to women with perinatal HIV infection were more likely to be small for gestational age.23 

Transition of Adolescents into Adult HIV Care Settings 

Facilitating a smooth transition of adolescents with chronic health conditions from their pediatric/adolescent medical home to adult care can be difficult and is especially challenging for HIV-infected adolescents. Transition is described as “a multifaceted, active process that attends to the medical, psychosocial, and educational or vocational needs of adolescents as they move from the child-focused to the adult-focused health-care system.”24 Care models for children and adolescents with perinatally acquired HIV tend to be family-centered, consisting of a multidisciplinary team that often includes pediatric or adolescent physicians, nurses, social workers, and mental health professionals. These providers generally have long-standing relationships with patients and their families, and care is rendered in discreet, more intimate settings. Although expert care is also provided under the adult HIV care medical model, an adolescent may be unfamiliar with the more individual-centered, busier clinics typical of adult medical providers and uncomfortable with providers with whom he or she often does not have a long-standing relationship. Providing an adolescent and an adult medical care provider with support and guidance regarding expectations for each partner in the patient-provider relationship may be helpful. In this situation, it may also be helpful for a pediatric and an adult provider to share joint care of a patient for a period of time. Providers should also have a candid discussion with a transitioning adolescent to understand what qualities the adolescent considers most important in an adult care setting (e.g., confidentiality, small clinic size, after-school appointments). Some general guidelines about transitional plans and who might benefit most from them are available.25-30 Pediatric and adolescent providers should have a formal plan to transition adolescents to adult care.

Outcomes are variable in young adult patients transitioned to adult care. In a recent study, 10% of 18-year-olds were lost to follow-up with care at an adult HIV site associated with a greater likelihood of attrition.31 Definitions of “successful transition” have ranged from the ability to maintain a certain level of follow-up in the new clinic, to laboratory measures of stability, to comparisons of younger and older adult patients.32-34 Factors that should be taken into consideration during transition include social determinants such as developmental status, behavioral/mental health issues, housing, family support, employment, recent discharge from foster care, peer pressure, illicit drug use, and incarceration. Currently there is no definitive model of transition to adult care, but in one study, adherence to medical visits just prior to the transition was predictive of successful transfer.32 Psychiatric comorbidities and their effective management also predict adherence to medical care and therapy.35-37


  1. Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. Jun 1 2011;57(2):165-173. Available at
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at Accessed on August 17, 2012.
  3. Rogers A. Pharmacokinetics and pharmacodynamics in adolescents. January 20-21, 1994. Proceedings. J Adolesc Health. Dec 1994;15(8):605-678. Available at
  4. Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. Jun 18 2010;59(RR-4):1-86. Available at
  5. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.Available at Accessed on January 13, 2014.
  6. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. Nov 28 2011;25(18):2301-2304. Available at
  7. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care. Jun 2008;13(2):123-132. Available at
  8. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149-156. Available at
  9. Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011;16(2):157-164. Available at
  10. Anderson MS, Hanley WD, Moreau AR, et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol. Apr 2011;71(4):616-620. Available at
  11. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception. Feb 2008;77(2):84-90. Available at
  12. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. Feb 2007;81(2):222-227. Available at
  13. Beksinska ME, Smit JA, Ramkissoon A. Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women. J Acquir Immune Defic Syndr. Aug 2010;54(4):e5. Available at
  14. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. Dec 2010;55(4):473-482. Available at
  15. Cruz ML, Cardoso CA, Joao EC, et al. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS. Nov 13 2010;24(17):2727-2731. Available at
  16. Elgalib A, Hegazi A, Samarawickrama A, et al. Pregnancy in HIV-infected teenagers in London. HIV Med. Aug 29 2010. Available at
  17. Meloni A, Tuveri M, Floridia M, et al. Pregnancy care in two adolescents perinatally infected with HIV. AIDS Care. Jun 2009;21(6):796-798. Available at
  18. Williams SF, Keane-Tarchichi MH, Bettica L, Dieudonne A, Bardeguez AD. Pregnancy outcomes in young women with perinatally acquired human immunodeficiency virus-1. Am J Obstet Gynecol. Feb 2009;200(2):149 e141-145. Available at
  19. Kenny J, Williams B, Prime K, Tookey P, Foster C. Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV. HIV Med. May 2012;13(5):304-308. Available at
  20. Agwu AL, Jang SS, Korthuis PT, Araneta MR, Gebo KA. Pregnancy incidence and outcomes in vertically and behaviorally HIV-infected youth. JAMA. Feb 2 2011;305(5):468-470. Available at
  21. Koenig LJ, Pals SL, Chandwani S, et al. Sexual transmission risk behavior of adolescents With HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr. Nov 2010;55(3):380-390. Available at
  22. Setse RW, Siberry GK, Gravitt PE, et al. Correlates of sexual activity and sexually transmitted infections among human immunodeficiency virus-infected youth in the LEGACY cohort, United States, 2006. Pediatr Infect Dis J. Nov 2011;30(11):967-973. Available at
  23. Jao J, Sigel KM, Chen KT, et al. Small for gestational age birth outcomes in pregnant women with perinatally acquired HIV. AIDS. Apr 24 2012;26(7):855-859. Available at
  24. Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider perspectives. Pediatrics. Jan 2005;115(1):112-120. Available at
  25. Rosen DS, Blum RW, Britto M, Sawyer SM, Siegel DM, Society for Adolescent M. Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the Society for Adolescent Medicine. J Adolesc Health. Oct 2003;33(4):309-311. Available at
  26. Gilliam PP, Ellen JM, Leonard L, Kinsman S, Jevitt CM, Straub DM. Transition of adolescents with HIV to adult care: characteristics and current practices of the adolescent trials network for HIV/AIDS interventions. J Assoc Nurses AIDS Care. Jul-Aug 2011;22(4):283-294. Available at
  27. New York State Department of Health AIDS Institute. Transitioning HIV-Infected Adolescents into Adult Care. 2011. Available at 
  28. Andiman WA. Transition from pediatric to adult healthcare services for young adults with chronic illnesses: the special case of human immunodeficiency virus infection. J Pediatr. Nov 2011;159(5):714-719. Available at
  29. Dowshen N, D'Angelo L. Health care transition for youth living with HIV/AIDS. Pediatrics. Oct 2011;128(4):762-771. Available at
  30. Committee On Pediatric Aids. Transitioning HIV-infected youth into adult health care. Pediatrics. Jul 2013;132(1):192-197. Available at
  31. Agwu A. Factors associated with falling out of care for older adolescents in the HIV research network. 19th International AIDS Conference; 2012; Washington, DC.
  32. Arazi-Caillaud SE, Mecikovsky D. Transition of HIV-Infected Adolescents to Adult HIV Care: 2 Years of Follow-up, Abstract CDB426. IAS; July 17-20, 2011; Rome, Italy.
  33. Saavedra-Lozano J, Navarro M, et al. Status of Vertically-Acquired HIV-Infected Children at the Time of Their Transfer to an Adult Clinic, Abstract 693. Conference on Retroviruses and Opportunistic Infections (CROI); 2011; Boston, MA.
  34. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr. Oct 1 2011;58(2):193-197. Available at
  35. Mellins CA, Tassiopoulos K, Malee K, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDS. Jul 2011;25(7):413-422. Available at
  36. Kapetanovic S, Wiegand RE, Dominguez K, et al. Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy-experienced perinatally HIV-infected youth. AIDS Patient Care STDS. Aug 2011;25(8):493-501. Available at
  37. Fish R, Judd A, Jungmann E, O'Leary C, Foster C, Network HIVYP. Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit. HIV Med. Sep 25 2013. Available at

Back to Top